
|Articles|August 9, 2022
Daily Medication Pearl: Sodium Polystyrene Sulfonate (Kayexalate)
Author(s)Saro Arakelians, PharmD
Kayexalate is a potassium binder indicated for the treatment of hyperkalemia.
Advertisement
Medication Pearl of the Day: Sodium Polystyrene Sulfonate (Kayexalate)
Indication: Kayexalate is a potassium binder indicated for the treatment of hyperkalemia.
Insight:
- Dosing: The average total daily adult oral dose of Kayexalate is 15 g to 60 g, administered as a 15-g dose (4 level teaspoons), 1 to 4 times daily.
- Dosage forms: Kayexalate is available as a cream to light brown, finely ground powder.
- Adverse events: Reported adverse reactions include anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, and vomiting.
- Mechanism of action: Kayexalate increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. The binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5

















































































































































































































